Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galinpepimut-S maintenance therapy in AML second complete remission
NCT04229979Phase 3Active, not recruiting
- Sponsor
- SELLAS Life Sciences Group, Inc.
- Start
- Feb 2021
- Primary completion
- Dec 2025
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 10
01
Overview
A Phase 3 trial of galinpepimut-s in acute myeloid leukemia (AML), sponsored by SELLAS Life Sciences Group, Inc.. Started Feb 2021; status: active, not recruiting.
02
Drugs
galinpepimut-s
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04229979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04229979.